Implications for Practice
non-clear cell renal cell carcinoma
Treatment options for patients with non-clear cell renal cell carcinoma (nccRCC) are limited. In this study, the authors specifically evaluated the outcomes of patients with nccRCC subtypes who enrolled in a clinical trial investigating the activity of the selective anti-angiogenic therapy tivozanib. It was found that tivozanib was active and well tolerated in patients with different nccRCC subtypes, suggesting tivozanib might be considered a treatment option for this patient population.